Summit Therapeutics Beats Q1 Loss Estimates, Adjusted Loss Narrows; Key FDA Decision Date Set
SMMT sits 40% above its 52-week low of $13.83.
Summary
Summit Therapeutics reported a Q1 adjusted loss of -$0.15 per share, which was narrower than the -$0.18 consensus estimate from analysts. This positive surprise comes despite an increase in R&D costs, primarily driven by the expansion of clinical trials for its lead drug candidate, ivonescimab. The company also provided crucial updates on its pipeline, expecting final PFS data from the HARMONi-3 squamous cohort in the second half of 2026, and PFS data for the non-squamous cohort in the first half of 2027. Most significantly, the FDA decision on the ivonescimab BLA is now expected by November 14, 2026, providing a clear near-term catalyst for the stock. This earnings beat and regulatory timeline update are material for a biotech company of this size, especially following the substantial net loss reported in the prior fiscal year.
At the time of this announcement, SMMT was trading at $19.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.7B. The 52-week trading range was $13.83 to $30.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.